Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumorsDik J. Kwekkeboom, Eric P. Krenning, Boen L.R. Kam et al.|Endocrine Related Cancer|2009Cited by 462
Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experienceRoelf Valkema, Eric P. Krenning, Marion de Jong et al.|Seminars in Nuclear Medicine|2002Cited by 433
Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.Dik J. Kwekkeboom, Eric P. Krenning, Jan Mueller‐Brand et al.|PubMed|2005Cited by 375
Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findingsMarion de Jong, Eric P. Krenning, Dik J. Kwekkeboom et al.|Seminars in Nuclear Medicine|2002Cited by 347
Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.Roelf Valkema, Eric P. Krenning, Stanislas Pauwels et al.|PubMed|2005Cited by 334